High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.

@article{Chan2011HighdoseFB,
  title={High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.},
  author={Sammy Yat Man Chan and Elaine Kingwell and J D en M Oger and Eric M Yoshida and Helen Tremlett},
  journal={Multiple sclerosis},
  year={2011},
  volume={17 3},
  pages={361-7}
}
BACKGROUND Post-marketing studies and case reports have linked beta-interferon (IFNβ) treatment with liver enzyme abnormalities and liver injuries in patients with multiple sclerosis (MS). Few predictors of risk exist. OBJECTIVE We investigated the effect of IFNβ and other patient characteristics on levels of the liver enzyme, alanine aminotransferase (ALT). METHOD Repeated ALT test results were reviewed retrospectively for 1064 MS patients prescribed an IFNβ as their first immunomodulatory… CONTINUE READING